Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Total Non-Current Liabilities of $11.7 billion for Q1 2026, up 2.22% year-over-year from $11.4 billion in Q1 2025, and up 1.41% quarter-over-quarter from $11.5 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $11.7 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 2.22% year-over-year to $11.7 billion; the TTM figure through Mar 2026 stood at $11.7 billion (up 2.22% YoY), while the FY2025 annual figure was $11.5 billion, down 3.28% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $11.7 billion, up from $11.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $12.1 billion in Q3 2024, with the low at $10.3 billion in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $11.2 billion (2025), against an average of $11.3 billion.
- Peak annual rise in Total Non-Current Liabilities reached 75.09% in 2022, while the deepest fall reached 16.85% in 2022.
- Jazz Pharmaceuticals' Total Non-Current Liabilities stood at $10.7 billion in 2022, then grew by 5.42% to $11.3 billion in 2023, then advanced by 5.81% to $11.9 billion in 2024, then retreated by 3.28% to $11.5 billion in 2025, then grew by 1.41% to $11.7 billion in 2026.
- Business Quant data shows JAZZ's Total Non-Current Liabilities at $11.7 billion in Q1 2026, $11.5 billion in Q4 2025, and $11.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 10.94 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.94 Bn |
| Mar 31, 2026 | 11.70 Bn |
| Dec 31, 2025 | 11.53 Bn |
| Sep 30, 2025 | 11.25 Bn |
| Jun 30, 2025 | 10.85 Bn |
| Mar 31, 2025 | 11.44 Bn |
| Dec 31, 2024 | 11.93 Bn |
| Sep 30, 2024 | 12.14 Bn |
| Jun 30, 2024 | 11.26 Bn |
| Mar 31, 2024 | 11.23 Bn |
| Dec 31, 2023 | 11.27 Bn |
| Sep 30, 2023 | 11.08 Bn |
| Jun 30, 2023 | 11.13 Bn |
| Mar 31, 2023 | 10.94 Bn |
| Dec 31, 2022 | 10.69 Bn |
| Sep 30, 2022 | 10.26 Bn |
| Jun 30, 2022 | 11.07 Bn |
| Mar 31, 2022 | 11.64 Bn |
| Dec 31, 2021 | 12.16 Bn |
| Sep 30, 2021 | 12.34 Bn |